Skip to search formSkip to main contentSkip to account menu

darusentan

Known as: (+)-(S)-2-((4,6-dimethoxy-2-pyrimidinyl)oxy)-3-methoxy-3,3-diphenylpropionic acid, benzenepropanoic acid, alpha-((4,6-dimethoxy-2-pyrimidinyl)oxy)-beta-methoxy-beta-phenyl-, (S)- 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
When Yanagisawa et al. 1 first identified endothelin (ET), a novel polypeptide vasoconstrictor for which numerous other functions… 
2008
2008
Objective: To summarize the role of the endothelin system (ETS) in cardiovascular disease (CVD) and evaluate the potential… 
2008
2008
The endothelins are a family (ET-1, ET-2, and ET-3) of naturally occurring polypeptides, with ET-1 being the most clinically… 
2006
2006
An impairment of cardiac norepinephrine (NE) reuptake via the neuronal NE transporter (NET) enhances the effects of increased… 
2003
2003
The present study evaluated the effects of long-term treatment with the endothelin A (ETA) receptor antagonist darusentan… 
2003
2003
Objective Secondary activation of the renin–angiotensin system plays a major role in the progression of chronic nephropathies… 
Highly Cited
2002
Highly Cited
2002
Objectives and design Isolated systolic hypertension (ISH) is the predominant form of hypertension in the elderly population and… 
2002
2002
This study investigated vascular reactivity in response to acetylcholine, in the presence of acute inhibition of nitric oxide… 
Highly Cited
2001
Highly Cited
2001
Background Sympathetic hyperactivity is observed in several disease states and may contribute to cardiovascular hypertrophic…